Search - tctmd.com

Displaying 181 - 200 of 389

Sort: Relevancy | Date

Presentation TCT 2016

ABSORB III Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Ron Waksman

October 31, 2016

Presentation TCT 2016

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

Presenter: Owen Faris, Mitchell W. Krucoff, Michael R Minogue

October 31, 2016

Presentation TCT 2016

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

Presentation TCT 2016

Introductory Lecture: Defining CHIP/Complex PCI in 2016 - Where We Are and Where We Need to Go

Presenter: Emmanouil S. Brilakis, Jeffrey W. Moses

October 31, 2016

Presentation TCT 2016

Keynote Lecture III. National Evaluation System for Health Technology (NEST): Objectives, Accomplishments and Future Directions

Presenter: Owen Faris, Mitchell W. Krucoff, Gregory Daniel

October 31, 2016

Presentation TCT 2016

Strengths and Limitations of Post-Approval Registries as Vehicles to Track Safety and Inform Device Label Expansion

Presenter: Owen Faris, Mitchell W. Krucoff, David R. Holmes Jr.

October 31, 2016

Presentation TCT 2016

Device Performance in Pre-Approval Studies vs Unrestricted Real-World Use: Lessons Learned and Future Opportunities

Presenter: Owen Faris, Mitchell W. Krucoff

October 31, 2016

Presentation TCT 2016

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Alan G. Fraser

October 31, 2016

Presentation TCT 2016

Key Note Lecture I. FDA/CDRH State of the Union

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Jeffrey Shuren

October 31, 2016

Presentation TCT 2016

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

Presenter: Matthew G. Hillebrenner, Gregg W. Stone

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

News Conference News TCT 2016

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

Severe Asymptomatic AS

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, Philippe Généreux

October 31, 2016

Presentation TCT 2016

Severe AS With Simple and Complex CAD

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, Alan Zajarias

October 31, 2016

Presentation TCT 2016

Severe AS With Simple and Complex CAD

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, David Hildick-Smith

October 31, 2016

News Conference News TCT 2016

EXCEL 和 NOBLE：左主干 PCI/CABG 的选择结果相悖

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

Severe AS and Hypertrophic Cardiomyopathy

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, Paul Sorajja

October 31, 2016

Advertisement

ABSORB III Critique: Pros and Cons

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Introductory Lecture: Defining CHIP/Complex PCI in 2016 - Where We Are and Where We Need to Go

Keynote Lecture III. National Evaluation System for Health Technology (NEST): Objectives, Accomplishments and Future Directions

Strengths and Limitations of Post-Approval Registries as Vehicles to Track Safety and Inform Device Label Expansion

Device Performance in Pre-Approval Studies vs Unrestricted Real-World Use: Lessons Learned and Future Opportunities

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Key Note Lecture I. FDA/CDRH State of the Union

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

Severe Asymptomatic AS

Severe AS With Simple and Complex CAD

Severe AS With Simple and Complex CAD

EXCEL 和 NOBLE：左主干 PCI/CABG 的选择结果相悖

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Severe AS and Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content